Neutrophil–to–Lymphocyte Ratio Predicts Survival After Whole-brain Radiotherapy in Non-small Cell Lung Cancer
2018; Stanford University Highwire Press; Volume: 33; Issue: 1 Linguagem: Inglês
10.21873/invivo.11459
ISSN1791-7549
AutoresHiroshi Doi, Kiyoshi Nakamatsu, Shimpei Anami, Kohei Fukuda, Masahiro Inada, Hitoshi Tatebe, Kazuki Ishikawa, Shuichi Kanamori, Hajime Monzen, Yasumasa Nishimura,
Tópico(s)Cancer Immunotherapy and Biomarkers
ResumoThis study aimed to identify prognostic factors for response to whole-brain radiotherapy (WBRT) in patients with brain metastases (BMs) from non-small cell lung cancer (NSCLC).This study retrospectively evaluated 100 patients who underwent WBRT for BMs from NSCLC between December 2012 and October 2017. Clinical factors were tested for associations with overall survival after WBRT.The median follow-up time was 134 days (range=14-1,395 days), the median survival time was 143 days, and the 1-year survival rate was 30.4%. Univariate and multivariate analyses revealed that better survival was independently associated with expression of programmed death-ligand 1 (PD-L1), no previous treatment for BMs, no extracranial disease, and a neutrophil-to-lymphocyte ratio (NLR) of <5.0.A low NLR and positive PD-L1 expression independently predict better prognosis in patients with BMs from NSCLC after WBRT. These findings suggest that the potential immune response may influence survival among patients with BMs.
Referência(s)